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18F-FDG-PET/MR increases diagnostic confidence in
detection of bone metastases compared with 18F-FDG-PET/CT
Andrei Samarina,e, Martin Hüllnera,c,d, Marcelo A. Queiroza, Paul Stolzmanna,b,d,
Irene A. Burgera,b,d, Gustav von Schulthessa and Patrick Veit-Haibacha,b,d
Purpose The aim of this study was to compare detection,
lesion conspicuity and reader confidence of
18F-fluorodeoxyglucose (18F-FDG)-PET/MR and 18F-FDG-
PET/computed tomography (CT) in patients with 18F-FDG
avid bone metastases.
Materials and methods In this prospective study, a total of
30 PET/CT and PET/MRI data sets were performed in 24
patients. Each examination was evaluated for the presence
of PET-positive bone lesions consistent with metastatic
involvement. Conspicuity of PET-positive bone lesions was
evaluated on the corresponding PET/CT and PET/MR
images and compared using the Wilcoxon signed-ranks
test. Reader confidence was determined to evaluate
whether PET/CT or PET/MR was more useful for the
assessment of the bone metastases and was compared
using Student’s t-test.
Results Overall, in both examinations, PET/CT and PET/
MRI detected 86 18F-FDG-positive bone lesions. On all 30
PET/MRI examinations, at least one morphological
correlate for 18F-FDG-positive bone lesions was found on
the MR component (82 out of 86 lesions). PET/CT imaging
allowed identification of corresponding structural changes
on the CT component in 23 out of 30 studies (65 out of 86
lesions). In lesion-by-lesion analysis, the mean lesion
conspicuity was significantly better on T1 fat MR imaging
compared with CT imaging (P= 0.005). In seven out of 30
studies, a significant increase in reader confidence of
PET/MRI compared with PET/CT was found.
Conclusion PET/MRI offers higher reader confidence and
improved conspicuity in bone metastases compared with
PET/CT. However, the overall detection rate was not
different. The highest possible clinical impact of PET/MRI
appears to be in patients with limited, early bone metastatic
disease. Nucl Med Commun 00:000–000 Copyright © 2015
Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
The presence of bone metastases is a major prognostic
factor in patients with oncological disease. Early and
confident detection of bone metastases enables accurate
staging and selection of the optimum treatment of
oncological disease.
Multiple imaging techniques are currently available for
the detection of the metastatic bone disease including
bone scintigraphy, CT, MR and PET/CT imaging [1,2].
Recently, PET/MR hybrid imaging was introduced as a
promising tool in oncological imaging research [3]. One of
the potential benefits of PET/MR compared with other
imaging modalities may be improved detection and
characterization of bone metastases.
Whole-body MR imaging has been shown to have superior
diagnostic accuracy compared with CT and bone scinti-
graphy in detection of bone metastases because of its
ability to assess early infiltration of bone marrow that pre-
cedes osteoblastic and osteoclastic response of the bone
matrix to malignant tissue infiltration [4,2,5–7]. The
comparison of whole-body MR and PET/CT for the
detection of bone metastases in solid tumours and hae-
matological malignancies yielded heterogeneous results
depending on the tumour histology and the PET tracer
used [8–14]. Importantly, integrated PET/CT has been
reported to show a high positive predictive value of 98% for
identification of bone metastases when both PET and CT
components of the examination are concordant [15].
However, when CT and PET results are discordant, the
positive predictive value of PET/CT significantly decrea-
ses to 61% [15]. The implementation of hybrid PET/MR
imaging may potentially improve detection of early bone
marrow infiltration, reduce the number of discordant
findings and therefore increase diagnostic confidence in
the detection and evaluation of bone metastasis.
It is not yet clear whether PET/MR provides a clinical
benefit compared with PET/CT for the detection and
evaluation of bone metastasis.
The aim of our study was to compare detection, lesion
conspicuity and reader confidence of 18F-FDG-PET/MR
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and 18F-FDG-PET/CT in patients with 18F-FDG avid
bone metastases.
Materials and methods
Patients
In this prospective study, 24 patients (nine men, 15
women; median age 61.5 years, range 43–89 years)
underwent sequential whole-body trimodality 18F-FDG-
PET/CT – MR between May 2011 and June 2013 as a
part of clinical work-up for either staging or restaging/
follow-up of various malignant tumours and suspicion of
bone metastases (30 examinations). The primary diseases
were breast cancer (12 patients), lung cancer (three
patients), tonsil cancer (two patients), non-Hodgkin
lymphoma (two patients) and carcinoma of the urethra,
gastric cancer, cervical cancer, spindle cell skin cancer
and medullary thyroid carcinoma (one patient each).
Clinical indication for the PET/CT-examination was
therapy follow-up (11 exams), primary staging (10 exams)
and restaging (nine exams). All patients had histological
confirmation of their primary disease. The mean follow-
up period was 18.5 months (range: 12–36 months). No
further selection was applied for patient inclusion.
Patients unwilling to undergo an additional MR exam-
ination, those who had claustrophobia and those with
MR-incompatible medical devices (e.g. cardiac pace-
maker, insulin pump, neurostimulator, cochlear implant)
were not considered for study inclusion. Six out of 24
patients underwent the PET/CT+MR study twice
(mean interval 311 days) and, therefore, 30 studies were
available for overall analysis. This study was approved by
the institutional ethics committee and written informed
consent was obtained from all patients before the
examination. Patient characteristics are summarized in
Table 1.
Image acquisition
Sequential PET/CT and MR imaging was performed on
a trimodality PET/CT-MR set-up (full-ring, time-of-
flight Discovery PET/CT 690 and a 3-T Discovery MR
750; both GE Healthcare, Waukesha, Wisconsin, USA).
Patients fasted for at least 4 h before injection of a stan-
dard dose of an average of 4.5MBq /kg body weight of
18F-FDG.
After injection, all patients were positioned on a dedi-
cated shuttle board that was placed on top of the MR
table. Patients had a resting time of ∼ 30 min before
going into the MR. A mechanism able to transfer the
shuttle board from the MR-table to the PET/CT table
ensured that patient transport from the MR system to the
PET/CT and placement/removal of dedicated radio-
frequency coils were possible without repositioning the
patient [16]. With this, image sets of PET/CT and PET/
MR were available for diagnostic and comparative pur-
poses. After placing the patient onto the shuttle board, a
dedicated radiofrequency coil (GEM 32-channel torso
coil, posterior and anterior array combined; GE
Healthcare) was positioned on the patient. The MR
imaging protocol consisted of three different sequences.
Whole-body multisection imaging was performed using a
T1-weighted three-dimensional (3D) dual-echo gradient-
recalled echo pulse sequence [liver accelerated volume
acquisition (LAVA)-Flex; GE Healthcare]. LAVA
acquisition was performed during end-expiratory breath-
hold for breathing sensitive areas (thorax, abdomen).
Whole-body multisection imaging was also performed
with a coronally acquired short TI inversion recovery
(STIR) sequence using parallel imaging. No breath-hold
technique was used. Finally, a T2-weighted sequence
with motion correction [periodically rotated overlapping
parallel lines with enhanced reconstruction (Propeller);
GE Healthcare] was acquired using a breathing trigger in
the thorax. This sequence was used for enhanced
breathing-triggered lung imaging. The total MR acqui-
sition time was ca. 16 min. Detailed acquisition para-
meters for all MR sequences are presented in Table 2.
After completion of the MR examination, patients were
shuttled to the PET/CT.
Low-dose CT data were acquired for PET attenuation
correction (AC) and for diagnostic purposes. Tube vol-
tage was 120 kV (peak), reference tube current was
12.35 mA/slice, automated dose modulation range was
15–80mAs/slice, collimation was 64× 0.625 mm, pitch
was 0.984 : 1, rotation time was 0.5 s, field of view (FOV)
was 50 cm and noise index was 20%. CT image sets were
reconstructed using an iterative algorithm (Adaptive
Statistical Iterative Reconstruction; GE Healthcare). The
PET data were acquired in 3D TOF mode with a scan
duration of 2 min per bed position, an overlap of bed
Table 1 Patient characteristics
Patient number Age (years) Sex Diagnosis
1 46 F Breast carcinoma
2 89 F Breast carcinoma
3 54 F Breast carcinoma
4 50 F Breast carcinoma
5 44 F Breast carcinoma
6 61 M Renal carcinoma. Tonsil carcinoma
7 48 M Malignant lymphoma
8 58 M Spindle cell skin cancer
9 69 M Medullary thyroid carcinoma
10 49 F Breast carcinoma
11 81 F Cancer of the uterine cervix
12 83 F Breast carcinoma
13 44 F Adenocarcinoma of the stomach
14 43 F Lung adenocarcinoma
15 62 F Breast carcinoma
16 69 M Lung adenocarcinoma
17 66 F Breast carcinoma
18 63 M Malignant lymphoma
19 69 M Lung adenocarcinoma
20 64 M Carcinoma of the urethra
21 49 F Breast carcinoma
22 78 F Breast carcinoma
23 67 M Tonsil carcinoma
24 58 F Breast carcinoma
F, female; M, male.
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positions of 23%, an axial FOV of 153 mm and a 700 mm
diameter FOV. The emission data were corrected for
attenuation using the low-dose CT (CTAC) and itera-
tively reconstructed [matrix size 256× 256, VUE Point
FX (3D TOF-OSEM) with three iterations, 18 subsets].
Images were filtered in image space using an in-plane
Gaussian convolution kernel with a full-width at half-
maximum of 4.0 mm, followed by a standard axial filter
with a three-slice kernel. This procedure has been used
in this standard manner in other studies as well [17].
Image processing
The PET, CT and MR images acquired were sent to a
dedicated review workstation (Advantage workstation,
version 4.6; GE Healthcare) that enables simultaneous
review of PET, CT and MR images side by side or in
fused/overlay mode (PET/CT, PET/MR). For this study,
PET/CT and PET/MRI data sets were compared. The
standard of reference consisted of histology (if available)
or follow-up with at least one additional cross-sectional
imaging examination.
Image analysis
Assessment of lesions in all below-mentioned categories
was performed by two readers (certified in radiology and
nuclear medicine) in consensus. PET/CT was evaluated
first. Then, with a time gap of 6 weeks, the PET/MR
images were also evaluated by the same readers in con-
sensus. The readers were blinded to any possible pre-
vious PET/CT or MR imaging. However, the readers
were aware of the diagnosis of the patients and were
aware of the clinical question for the respective clinical
PET/CT.
Detection of PET-positive bone lesions
First, each PET examination was evaluated for the pre-
sence of PET-positive bone lesions. Lesions were con-
sidered PET positive if their maximum standardized
uptake value (SUVmax) was significantly higher than liver
uptake. In cases where increased uptake was visible but
inferior to liver uptake, the surrounding tissue was taken
as a reference. For every lesion SUVmax, the mean stan-
dardized uptake value (SUVmean), total lesion glycolysis
and metabolic tumour volume (PETvol) were measured.
The threshold value as percentage of SUVmax was
adjusted manually for each lesion such that the borders of
the volume of interest only included activity that could
be ascribed to the lesion. The location and the number of
the lesions were recorded. Up to ten PET-positive
lesions were evaluated per patient with a maximum of
three lesions per body compartment (e.g. cervical, thor-
acic, lumbar spine, pelvis). In patients with multiple
confluent lesions in the same compartment, lesions that
were clearly distinguishable from each other were selec-
ted for analysis. 18F-FDG-negative lesions with benign
radiological appearance were not evaluated in this study.
Lesion conspicuity
The conspicuity of PET-positive bone lesions was eval-
uated on the corresponding PET/CT and PET/MR
images. For this analysis, the conspicuity of the mor-
phological imaging component was assessed (CT or MR).
Lesions were assessed on the basis of a five-point scale:
grade 0 – lesion was not detectable, grade 1 – 1–25%
lesion contour detectable, grade 2 – 26–50% contour
detectable, grade 3 – 51–75% contour detectable and
grade 4 – 76–100% contour detectable. The evaluation
described was applied for all the reconstructions of the
T1-weighted 3D gradient echo sequence (in-phase, out-
phase, fat and water), for the whole-body STIR sequence
and for the CT images. A time gap of 6 weeks between
the assessment of PET/CT and PET/MR images was
applied to eliminate potential bias.
Lesion size
Measurements of the maximum lesion diameters on CT
andMR images were obtained. Lesions not visible on the
CT or MR images were not measured in that particular
modality and noted as ‘not measurable’. Measurements
on the MRI component were taken on the reconstructed
T1 in-phase images.
Lesion density
All lesions were assigned to three groups on the basis of
their CT appearance. (a) Sclerotic lesions with pre-
dominantly an increase in bone density. (b) Lytic lesions
with predominantly destruction of bone tissue. (c)
18F-FDG-positive lesions without change in bone den-
sity, for example lesions not visible on CT imaging.
Table 2 Acquisition parameters for MR imaging
Parameters LAVA STIR Propeller
TR/TE (ms) 4.3/1.3 (OP),
2.6 (IP)
2000/42 9321/122
Flip angle 12° N/A N/A
Partial Fourier 0.9% N/A N/A
TI (ms) N/A 160 N/A
Partial imaging
acceleration factor
2 2 3
Slice thickness (mm) 4.0 6 4.5
FOV (cm) 50 50 40
Acquisition matrix (pixels) 288×224 384×224 288×288
Receiver bandwidth (kHz) 142.86 100 62.5
Acquisition time per body
section (s)
18 123 N/A
Body sections per patient 4 3 1
Total acquisition time (min) ca. 3 ca. 8 ca. 5
Coverage Whole body Whole body Chest, upper
abdomen
FOV, field of view; IP, in-phase; LAVA, liver accelerated volume acquisition,
T1-weighted 3D dual-echo gradient-recalled echo pulse sequence; OP, opposed
phase; Propeller, periodically rotated overlapping parallel lines with enhanced
reconstruction, T2-weighted sequence with motion correction; STIR, short TI
inversion recovery sequence; TE, time to echo; TI, inversion time; TR, time of
repetition.
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Reader confidence
Reader confidence was determined qualitatively to
evaluate whether PET/CT or PET/MR was more useful
for the assessment of the evaluated bone metastases. The
following score was used for assessment.
High reader confidence
18F-FDG-positive lesions had a morphologic correlate
and overall hybrid imaging findings correlated to meta-
static involvement – 2 points.
Moderate reader confidence
PET-positive findings are suggestive of metastatic dis-
ease, but only partially show a morphologic correlate – 1
point.
Low reader confidence
PET findings are inconclusive, no clear morphologic
correlate is seen for 18F-FDG-positive lesions – 0 points.
Statistical analysis
Ordinal variables were expressed as median (range),
nominal variables as mode (percentage) and ratio vari-
ables as geometric mean ± SD. For the purpose of clarity,
the conspicuity score was also expressed as mean ± SD.
The size and conspicuity of lesions in different mod-
alities were compared using the Wilcoxon signed-ranks
test for matched pairs. Size, conspicuity and PET para-
meters of lesions stratified by CT-density and location on
CT and MR images were compared using the
Mann–Whitney U-test for independent samples. Reader
confidence was compared using Student’s t-test. A
P-value of less than 0.05 was considered statistically sig-
nificant. All statistical analyses were carried out with IBM
SPSS Statistics 19.0.1 (IBM, Armonk, New York, USA).
Results
A total of 30 PET/CT and PET/MRI data sets were
performed in 24 patients. A total of 86 18F-FDG-positive
bone lesions were identified. In 12 data sets, patients had
multiple disseminated bone lesions, whereas in the
remaining 18 data sets, less than 10 lesions were present
in each patient. The metabolic and morphologic char-
acteristics of the lesions are summarized in Table 3.
Detection
Overall, in both examinations, PET/CT and PET/MRI
detected the same number of lesions on the basis of the
PET component (as both examinations used the same
PET-data set).
In those 30 data sets, 95% of analyzed 18F-FDG-positive
bone lesions (82/86 lesions) had a morphologic correlate
on the MR component. Thus, on all PET/MRI exam-
inations, at least one morphological correlate was found
on the MR component.
PET/CT imaging enabled identification of structural
changes on the CT component in 76% of the 18F-FDG-
positive lesions (65/86 lesions). A morphologic correlate
on the CT component of the PET/CT was clearly
identified in 23 PET/CT studies out of 30.
Overall, in seven examinations (seven patients),
18F-FDG-positive bone lesions (n= 9) were seen only on
the MR component without clearly visible changes of the
bony structure on CT. In two of these examinations (two
patients), patients had one single 18F-FDG-positive
lesion that was not visible on MR or CT images.
However, in both of these examinations, a single addi-
tional 18F-FDG-positive bone lesion (two lesions in total)
was seen again only on the MR component in a different
location. No additional lesions were seen on the CT
component in those cases. The remaining lesions that
were 18F-FDG positive but CT negative were all seen in
patients where several other bone metastases were
detected on both the PET component and the CT
component.
In two different examinations (two patients), the struc-
tural bone change in two 18F-FDG-positive lesions was
seen only in the CT component but not in the MRI
component. Again, in those patients, additional
18F-FDG-positive bone lesions (four lesions) showed a
morphological correlate on the MR component.
Reader confidence
The overall reader confidence on the basis of the above-
mentioned scale for PET/CT was 1.76 and 2.0 for PET/
MRI (P= 0.0029). PET/MR showed a high confidence in
all patients. However, in PET/CT, a high confidence was
found in 23 cases and a moderate confidence in seven
cases (Figs 1 and 2). In 23 studies, no change in reader
confidence was observed between PET/CT and PET/
Table 3 Summary of metabolic and morphologic characteristics of
all 18F-FDG-positive bone lesions
N Minimum Maximum Mean SD
Metabolic characteristics
SUVmax 86 2.2 29.7 7.96 5.2
SUVmean 86 1.2 14.2 4.6 2.69
TLG 86 477 441 931 32 243.91 77688.86
PETvol 86 0.42 83.8 5.74 12.1
Size (mm)
CT 65 4 84 17.03 16.77
MR T1 in-phase 82 5 85 20.63 17.2
Conspicuity, score
CT 86 0 4 2.35 1.62
MR STIR 86 0 4 2.23 1.57
MR T1 water 86 0 4 2.48 1.42
MR T1 fat 86 0 4 3.09 1.44
MR T1 in-phase 86 0 4 2.21 1.46
MR T1 out-phase 86 0 4 2.76 1.47
MR T1 water, fat, in-phase, out-phase, T1-weighted 3D dual-echo gradient-
recalled echo pulse sequence, liver accelerated volume acquisition, correspond-
ing water, fat, in-phase and out-phase reconstruction; MR STIR: short TI inversion
recovery sequence; PETvol, metabolic tumour volume; SUVmax, maximum stan-
dardized uptake value; SUVmean, mean standardized uptake value; TLG, total
lesion glycolysis.
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Fig. 1
Male patient (64 years old) with metastatic carcinoma of the urethra. (a) Three-dimensional 18F-FDG-PET image shows metastatic spread of the
cancer. A single 18F-FDG avid bone metastasis is present in the right iliac bone (black arrow). (b) On axial CT image, only the partially visible sclerotic
lesion is seen in the corresponding location (white arrow) – such findings can be easily overseen when reading CT images prospectively. (c) Fused
PET/CT axial image. (d, e) In contrast to the CT image, this single bone lesion is clearly depicted on axial MR images (white arrows) as a signal
increase on the T1 water image (d) and as a signal drop on the T1 fat image (e) compared with the normal bone marrow. (f, g) Corresponding fused
PET/MR images. In this case, PET/MR imaging provided higher reader confidence for the diagnosis of metastatic bone marrow involvement
compared with the PET/CT imaging as a morphologic correlate for the 18F-FDG avid bone lesion was clearly seen only on MR imaging. CT, computed
tomography; 18F-FDG, 18F-fluorodeoxyglucose.
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MR imaging. These patients either had several lesions
seen on both modalities or had multiple disseminated
lesions where the difference in the detection of single
lesions did not lead to a change in overall reader con-
fidence. Thus, in the seven studies in which all
18F-FDG-positive bone lesions (n= 9) were seen only on
the MR component, a significant increase was found in
reader confidence for PET/MRI versus PET/CT.
Lesion conspicuity
In lesion-by-lesion analysis, PET/MR imaging provided
better results in the detection of morphologic changes in
the 18F-FDG-positive bone lesions analysed: the mean
lesion conspicuity was significantly better on T1 fat MR
imaging compared with CT imaging (P= 0.005, Table 4).
The overall lesion conspicuity on STIR-weighted MR
images was similar to CT images.
Fig. 2
(a) (b)
(c)
(d) (e)
(f)
UV 40.0 cm
10.00
0.00
L
2
0
0
Female patient (43 years old) with adenocarcinoma of the lung. (a) Three-dimensional 18F-FDG-PET image shows metastatic spread of the cancer.
One of the multiple 18F-FDG avid bone metastases is present in the right ischium (black arrow). (b) Axial CT image shows clear osteolysis in the
corresponding location (white arrow). (c) Fused PET/CTaxial image. (d) Coronal STIR MR image and (e) axial T1 water image clearly depict the lesion
because of its high signal intensity (white arrows). (f) Corresponding axial fused PET/MR image. In this case, PET/CT and PET/MR imaging provided
equal reader confidence for the diagnosis of metastatic bone marrow involvement as a morphologic correlate for the 18F-FDG avid bone lesion was
clearly seen on both CT and MR images. CT, computed tomography; 18F-FDG, 18F-fluorodeoxyglucose.
Table 4 Comparison of lesions conspicuity scores between CT and
MR images
Lesions’ conspicuity P-value
MR STIR vs. CT 0.496
MR T1 water vs. CT 0.516
MR T1 fat vs. CT 0.005a
MR T1 in-phase vs. CT 0.834
MR T1 out-phase vs. CT 0.069
CT, computed tomography; MR T1 water, fat, in-phase, out-phase, T1-weighted
3D dual-echo gradient-recalled echo pulse sequence, liver accelerated volume
acquisition, corresponding water, fat, in-phase and out-phase reconstruction; MR
STIR: short TI inversion recovery sequence.
aThe mean lesion conspicuity was significantly higher on T1 fat MR imaging
compared with CT imaging.
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In the subanalysis based on lesions density (on the CT-
component), the mean conspicuity of neither lytic nor
sclerotic lesions was significantly different on T1 fat MR
imaging compared with CT imaging. However, the mean
conspicuity of both sclerotic and lytic lesions was sig-
nificantly higher on CT imaging compared with STIR
MR imaging (P= 0.014 and 0.004, respectively). Further
characteristics of this subanalysis are summarized in
Tables 5 and 6.
In the 21 18F-FDG-positive bone lesions without a cor-
responding structural change visible in PET/CT imaging
(65/86 were seen), the lesions were seen best in the T1
fat sequence of PET/MR imaging with a mean con-
spicuity of 3.52 and a mean size on T1 imaging of
19.5 mm. Further characteristics of these lesions are
summarized in Table 7. The mean size of the 18F-FDG-
positive bone lesions was found to be significantly larger
on T1-weighted MR images compared with CT images.
Discussion
In our study, we found that the overall detection rate of
PET/CT and PET/MRI was the same on the basis of the
18F-FDG positivity of the bone metastases
evaluated here.
However, we could show that lesion conspicuity as well
as reader confidence were improved in PET/MRI com-
pared with PET/CT on the basis of the soft tissue con-
trast of the MR component. Furthermore, several
morphological correlates were identified in PET/MRI
that were not present in PET/CT.
General
The superior soft tissue contrast and the consecutive
ability to assess early metastatic infiltration of bone
marrow make PET/MRI a promising modality in staging
and response assessment in metastatic bony disease
compared with PET/CT. However, compared with PET/
CT as a standard of reference, PET/MRI as a new
technology should have clear advantages in patient care
and should ideally not place additional examination
burden on the patients. There is a general workflow issue
currently discussed in the literature with current PET/
MRI protocols. Most of the protocols in such an early
phase of a new modality are just ‘normal’ MR protocols
that do not take into account the additional diagnostic
information of the PET component. However, in our
study, here, we evaluated a PET/MRI protocol that
consists of three noncontrast sequences that allow for a
whole-body PET/MRI approximately within the same
time than a standard PET/CT [17].
Current literature
Our study suggests that one of the clinical scenarios
where PET/MRI may be beneficial over PET/CT is an
oncological patient with only few early bone metastases.
In our series of patients, 25% of the lesions evaluated
showed no definite morphological change in the bony
structure on CT imaging whereas 95% of lesions had a
clear morphological correlate on MR imaging. Although
all these lesions were still detected because of their
18F-FDG avidity, in cases of low metabolic activity (e.g.
post-therapy), moving artefacts and small size, a patho-
logical 18F-FDG uptake in those lesions might not be
very obvious. In this situation, the clear depiction of
lesions on the MR component would ensure the detec-
tion of the lesions and correct distant staging of the
Table 5 Conspicuity scores (mean values) of the lesions on the
basis of their CT density
Lytic Sclerotic Nonvisible on CT
N of lesions (CT based) 48 17 21
CT score 3.08 3.18 0
MR STIR score 2.11 1.88 2.88
MR T1 water score 2.3 2.86 2.48
MR T1 fat score 2.77 3.37 3.52
MR T1 in-phase score 1.88 2.52 2.21
MR T1 out-phase score 2.53 3 3.05
CT, computed tomography; MR T1 water, fat, in-phase, out-phase, T1-weighted
3D dual-echo gradient-recalled echo pulse sequence, liver accelerated volume
acquisition, corresponding water, fat, in-phase and out-phase reconstruction; MR
STIR: short TI inversion recovery sequence.
Table 6 Comparison of sclerotic and lytic lesions conspicuity
scores between CT and MR images
Lesions’ conspicuity P-value
Lytic lesions
MR STIR vs. CT 0.004a
MR T1 fat vs. CT 0.309
Sclerotic lesions
MR STIR vs. CT 0.014b
MR T1 fat vs. CT 0.425
CT, computed tomography; MR T1 water, fat, in-phase, out-phase, T1-weighted
3D dual-echo gradient-recalled echo pulse sequence, liver accelerated volume
acquisition, corresponding water, fat, in-phase and out-phase reconstruction; MR
STIR: short TI inversion recovery sequence.
a,bMean conspicuity of both sclerotic and lytic lesions was significantly higher on
CT imaging compared with STIR MR imaging.
Table 7 Metabolic and morphologic characteristics (mean values)
of 18F-FDG-positive bone lesions nonvisible on CT by location
Thorax Spine Pelvis Extremities Total
N 2 7 6 6 21
Metabolic characteristics
SUVmax 4.6 7.4 17.6 7.8 10.1
SUVmean 2.2 4.3 8.3 4.9 5.4
Size (mm)
MR T1 in-phase 17 18.3 28.5 13.7 19.5
Conspicuity, score
MR STIR 1 2.3 3.7 3.7 2.9
MR T1 water 1 3.1 3.3 2.7 2.9
MR T1 fat 1 3.9 3 3.3 3.5
MR T1 in-phase 1 2.9 3 2.2 2.5
MR T1 out-phase 1 3.3 3.7 2.8 3.1
CT, computed tomography; 18F-FDG, 18F-fluorodeoxyglucose; MR T1 water, fat,
in-phase, out-phase, T1-weighted 3D dual-echo gradient-recalled echo pulse
sequence, liver accelerated volume acquisition, corresponding water, fat, in-phase
and out-phase reconstruction; MR STIR: short TI inversion recovery sequence;
SUVmax, maximum standardized uptake value; SUVmean, mean standardized
uptake value.
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disease. This observation is supported by the recent work
of Eiber et al. [18], who drew a similar conclusion .
The presence of 18F-FDG-positive bone lesions on PET
with negative findings at CT is not uncommon and is a
known clinical issue. In the study by Taira et al. [15], 27%
(31 out of 113) of 18F-FDG-positive bone lesions ana-
lysed were found to be CT negative. In addition, MRI
has been shown to find metastasis not visible on
18F-FDG-PET or CT imaging [9]. In an early compar-
ison, Antoch et al. [8] reported that MRI was more
accurate in evaluating the bone structure for the presence
of metastasis in a study comparing the staging accuracies
of whole-body MRI and PET/CT. These finding were
later supported in a study by Schmidt et al. [12], where
whole-body MR imaging was found to have superior
sensitivity and accuracy compared with PET/CT in the
detection of bone metastases [12]. Therefore, in PET/
MRI, even in cases of low 18F-FDG activity, the like-
lihood of correct detection and staging seems to be higher
than PET/CT. However, according to the results of our
study, in patients with a high likelihood of metastatic
bone disease, the use of PET/MRI would likely not
result in improved diagnostic confidence as both PET/
CT and PET/MRI would detect multiple lesions with no
further therapeutic consequence.
Overall, we found an improved lesion conspicuity as well
as higher reader confidence in the evaluation of PET/
MRI compared with PET/CT. The lesion-by-lesion
analysis showed that the highest lesion conspicuity was
achieved by PET/MR imaging using the T1-weighted
sequence highlighting the alterations in the bone marrow
(T1 fat reconstruction). The significant increase in
lesions conspicuity on MR imaging was mainly because
of 21 18F-FDG-positive bone lesions not visible on CT
imaging. These lesions likely represent bone marrow
infiltration that have not yet resulted in considerable
change in bone density but already changed signal in MR
imaging [1]. Interestingly, the mean size of these lesions
was quite substantial (19.5 mm). These results are partly
in agreement with a recent study with a similar number of
evaluated lesions [18]. There, PET/MRI with a
T1-weighted sequence in addition to the Dixon-based
AC sequence was superior in lesion delineation. Several
differences have to be noted compared with our study.
One of the reasons for the improved delineation in this
additional T1-weighted sequence might be the higher
matrix compared with the Dixon sequence. However,
overall detection was not significantly different.
Additional differences are that the PET/CT was partly
performed with contrast media compared with a non-
contrast PET/MRI. In our study, we strictly used non-
contrast PET/CT for our comparison. An important
aspect that was evaluated in our study was the reader
confidence. Interestingly, although overall lesion detec-
tion was the same between PET/CT and PET/MRI, the
additionally detectable lesions on the MRI component
obviously support the diagnostic confidence for the
reader – a fact that cannot be neglected in clinical routine
reading, again, especially in lesions with low 18F-FDG
uptake.
Several studies have evaluated the important issue of
differences in AC in PET imaging deriving from CT-
based AC or MR-based AC. Phantom studies showed an
increase in the relative error by up to 6.8% in the body
and up to 31.0% for bony regions when the bones are
ignored by the AC algorithm. In simulated clinical stu-
dies, the mean relative error may be as high 15% for body
lesions and 30.7% for bony lesions [19]. Differences for
the head and brain are lower [20]. These issues certainly
have an impact on the detection of metastatic bone dis-
ease in simultaneous PET/MRI. These issues are even
more pronounced when simulating therapy response,
where it was found that simulated PET AC leads to a
considerable underestimation of tracer uptake in bone
lesions. The underestimation is dependent on the lesion
composition with the largest error in sclerotic lesions [21].
As we used a trimodality set-up for our evaluation, we
cannot compare or comment on those differences; how-
ever, this might be considered an advantage of the tri-
modality set-up for scientific comparisons where no
underestimation can occur. Interestingly, in our patient
population, the mean conspicuity of neither lytic nor
sclerotic lesions was significantly different on T1 imaging
compared with CT density. However, there was a dif-
ference in sclerotic and lytic lesions compared with
STIR. This is remarkable, because usually – in MR
imaging – fat-saturated T2 imaging is considered the
ideal sequence to search for the major pathologies and
especially bone lesions [22,23]. In PET/MRI (or PET/
CT-MRI), the PET component is always available (no
choice), but one has a choice which sequences are being
used in the MR part of the examination. Thus, in the
context of PET/MR, the sequences of choice might be
different from those in MR imaging alone.
Limitation
The possible limitation of the study is that only
18F-FDG-positive bone lesions were selected for the
analysis. Thus, evaluation of benign lesions is not part of
this study. Histological verification of 18F-FDG-positive
bone lesions was not always possible (and ethically not
justifiable), but all patients had histological verification of
their primary disease and the available imaging and
clinical data were used to assess the analysed lesions on
the basis of standard imaging criteria. We did not evalu-
ate a possible clinical impact of PET/MR versus PET/
CT in our patient population.
Conclusion
PET/MRI offers higher diagnostic confidence and an
improved conspicuity in bone metastases compared with
PET/CT. However, the overall detection rate was not
8 Nuclear Medicine Communications 2015, Vol 00 No 00
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different. The highest possible clinical impact of PET/
MRI appears to be in patients with limited early bone
metastatic disease.
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